0001593034-16-000063.txt : 20160718 0001593034-16-000063.hdr.sgml : 20160718 20160718171154 ACCESSION NUMBER: 0001593034-16-000063 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20160718 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20160718 DATE AS OF CHANGE: 20160718 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Endo International plc CENTRAL INDEX KEY: 0001593034 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36326 FILM NUMBER: 161772017 BUSINESS ADDRESS: STREET 1: MINERVA HOUSE, SIMMONSCOURT ROAD STREET 2: BALLSBRIDGE CITY: DUBLIN 4 STATE: L2 ZIP: 00000 BUSINESS PHONE: 353-1-268-2000 MAIL ADDRESS: STREET 1: MINERVA HOUSE, SIMMONSCOURT ROAD STREET 2: BALLSBRIDGE CITY: DUBLIN 4 STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Endo International Ltd DATE OF NAME CHANGE: 20131203 FORMER COMPANY: FORMER CONFORMED NAME: Sportwell Ltd DATE OF NAME CHANGE: 20131126 8-K 1 a071820168-knoramcotermina.htm FORM 8-K Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________
FORM 8-K
_______________________________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): July 18, 2016

_______________________________
ENDO INTERNATIONAL PLC
(Exact Name of Registrant as Specified in Its Charter)  
_______________________________
Ireland
001-36326
68-0683755
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification No.)
First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland
Not Applicable
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code 011-353-1-268-2000
Not Applicable
Former name or former address, if changed since last report
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 





Item 1.02.     Termination of a Material Definitive Agreement
On July 18, 2016, the Registrant’s subsidiary, Endo Ventures Limited (“Endo”), provided written notice to Noramco, Inc. (“Noramco”) that Endo was terminating the Supply Agreement, dated as of April 27, 2012, by and between Endo (by assignment from Endo Pharmaceuticals Inc.) and Noramco (as amended, the “Supply Agreement”). The effective date of the termination is April 27, 2017. Endo is terminating the Supply Agreement in accordance with its terms and the termination will not give rise to any early termination fees or penalties.
Pursuant to the Supply Agreement, Noramco manufactures and supplies certain narcotic active drug substances, in bulk form, for inclusion in the controlled substance pharmaceutical products of the Registrant and its subsidiaries. There are no minimum annual purchase commitments under the Supply Agreement; however, the terms of the Supply Agreement require Endo to purchase from Noramco a fixed percentage of the Registrant and its subsidiaries’ annual requirements of each narcotic active drug substance covered by the Supply Agreement. The purchase price for these substances is equal to a fixed amount, adjusted on an annual basis based on volume.
A copy of the notice of termination is filed herewith as Exhibit 10.1 and is incorporated herein by reference.
Item 9.01.    Financial Statements and Exhibits.
(d)
Exhibits
Exhibit No.
Description
10.1
Notice of Termination, effective as of April 27, 2017, of the Supply Agreement





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 Dated: July 18, 2016
 
 
ENDO INTERNATIONAL PLC
(Registrant)
 
 
By:
/s/ Matthew J. Maletta
Name:
Matthew J. Maletta
Title:
Executive Vice President,
Chief Legal Officer







INDEX TO EXHIBITS
Exhibit No.
Description
10.1
Notice of Termination, effective as of April 27, 2017, of the Supply Agreement



 EX-10.1 2 ex101noramcoterminationlet.htm EXHIBIT 10.1 NORAMCO TERMINATION LETTER Exhibit
Exhibit 10.1

Noramco, Inc.
500 Swedes Landing Road
Wilmington, DE 19801
Attn: Vice President Sales and Marketing


July 18, 2016


Ladies and Gentlemen,

Reference is made to that certain Supply Agreement by and between Noramco, Inc. (“Noramco”) and Endo Ventures Limited (“Endo”) effective April 27, 2012 and as subsequently amended (collectively, the “Agreement”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.

Pursuant to Section 10.1 of the Agreement, this letter shall serve as written notice to Noramco of Endo’s non-renewal of the Agreement. As a result, upon the expiration of the Initial Term, the Agreement will terminate effective April 27, 2017. For the avoidance of doubt, the obligations and liabilities set forth in Section 10.5 of the Agreement shall survive such termination.

Thank you for your help in this matter and we look forward to continuing to do business with you in the future.

Very truly yours,

ENDO VENTURES LIMITED
 
 
By:
/s/ Robert Cobuzzi
Name:
Robert Cobuzzi
Title:
Director